Charlotta Preger

Charlotta Preger

Auto-generated profile, based on publicly available information

Charlotta Preger

KTH Royal Institute of Technology

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in Journal of Autoimmunity
Verified
Journal Article
Open access
CPCharlotta Preger
Charlotta Preger
ANAntonella Notarnicola
Antonella Notarnicola
CHCecilia Hellström
Cecilia Hellström
EWEdvard Wigren
Edvard Wigren
CFCátia Fernandes-Cerqueira
Cátia Fernandes-Cerqueira
PJPer-Johan Jakobsson
Per-Johan Jakobsson
Autoantibodies are thought to play a key role in the pathogenesis of idiopathic inflammatory myopathies (IIM). However, up to 40% of IIM patients, even those with clinical manifestations of anti-synthetase syndrome (ASSD), test seronegative to known myositis-specific autoantibodies. We hypothesized the existence of new potential autoantigens among human cytoplasmic aminoacyl tRNA synthetases (aaRS) in patients with IIM. Plasma samples from 217 patients with IIM according to 2017 EULAR/ACR criteria, including 50 patients with ASSD, 165 without, and two with unknown ASSD status were identified retrospectively, as well as age and gender-matched sera from 156 population controls, and 219 disease controls. Patients with previously documented ASSD had to test positive for at least one of the five most common anti-aaRS autoantibodies (anti-Jo1, -PL7, -PL12, -EJ, and -OJ) and present with one or more of the following clinical manifestations: interstitial lung disease, myositis, arthritis, Raynaud's phenomenon, fever, or mechanic's hands. Demographics, laboratory, and clinical data of the IIM cohort (ASSD and non-ASSD) were compared. Samples were screened using a multiplex bead array assay for presence of autoantibodies against a panel of 117 recombinant protein variants, representing 33 myositis-related proteins, including all nineteen cytoplasmic aaRS. Prospectively collected clinical data for the IIM cohort were retrieved and compared between groups within the IIM cohort and correlated with the results of the autoantibody screening. Principal component analysis was used to analyze clinical manifestations between ASSD, non-ASSD groups, and individuals with novel anti-aaRS autoantibodies. We identified reactivity towards 16 aaRS in 72 of the 217 IIM patients. Twelve patients displayed reactivity against nine novel aaRS. The novel autoantibody specificities were detected in four previously seronegative patients for myositis-specific autoantibodies and eight with previously detected myositis-specific autoantibodies. IIM individuals with novel anti-aaRS autoantibodies (n = 12) all had signs of myositis, and they had either muscle weakness and/or muscle enzyme elevation, 2/12 had mechanic's hands, 3/12 had interstitial lung disease, and 2/12 had arthritis. The individuals with novel anti-aaRS and a pathological muscle biopsy all presented widespread up-regulation of major histocompatibility complex class I. The reactivities against novel aaRS could be confirmed in ELISA and western blot. Using the multiplex bead array assay, we could confirm previously known reactivities to four of the most common aaRS (Jo1, PL12, PL7, and EJ (n = 45)) and identified patients positive for anti-Zo, -KS, and -HA (n = 10) that were not previously tested. A low frequency of anti-aaRS autoantibodies was also detected in controls. Our results suggest that most, if not all, cytoplasmic aaRS may become autoantigenic. Autoantibodies against new aaRS may be found in plasma of patients previously classified as seronegative with potential high clinical relevance.

13 July 2026 in Communications Medicine
Verified
Journal Article
Open access
JKJosefin Kenrick
Josefin Kenrick
CPCharlotta Preger
Charlotta Preger
MÁMaría Bueno Álvez
María Bueno Álvez
MUMaria Alejandra Ulloa
Maria Alejandra Ulloa
GBGöran Bergström
Göran Bergström
EPElisa Pin
Elisa Pin
Systemic autoimmune rheumatic diseases (SARDs) are a heterogeneous group of autoimmune conditions characterized by immune system dysregulation leading to chronic inflammation and tissue damage. The overlapping clinical manifestations make differential diagnosis challenging, highlighting the need for novel biomarkers to facilitate early diagnosis, stratification, and personalized treatment. Five SARDs including idiopathic inflammatory myopathies (n = 210), rheumatoid arthritis (n = 84), systemic sclerosis (n = 100), Sjögren disease (n = 99), and systemic lupus erythematosus (n = 99), as well as healthy controls (n = 400) and controls with acute infectious diseases (n = 218) were selected for plasma protein profiling using Olink Explore 1536. Differential abundance analysis and machine learning were used to identify proteins with both known and novel association to SARDs. The five SARDs share hundreds of proteins with consistently altered abundance compared to both healthy and infectious controls, reflecting common underlying molecular dysregulation. Despite the overlap, we identify multiple proteins with higher abundance specific to individual SARDs. Machine learning further enables accurate classification of the five SARDs, identifying a panel of 48 proteins with high discriminatory performance, several of which are also supported by differential abundance analysis. Altogether, this explorative cross-sectional study demonstrates the importance of a pan-disease approach, including also infectious and healthy controls, to identify robust and disease-informative protein panels for improved classification of SARDs. Protein levels from this study are available open access through the Human Protein Atlas, facilitating further plasma proteome research on autoimmune disease.

9 December 2025 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Open access
NKN Karami
N Karami
EWE Wigren
E Wigren
CPC Preger
C Preger
RGR Gallini
R Gallini
IGI Gunnarsson
I Gunnarsson
HIHelena Idborg
Helena Idborg
Interferon regulatory factor 5 (IRF5) plays a central role in interferon-mediated inflammation and is implicated in autoimmune diseases, including systemic lupus erythematosus (SLE). Detecting IRF5 in plasma is challenging due to its low circulating levels, highlighting the need for a highly sensitive and quantitative assay. This study aimed to develop such an assay, validate the existence of previously identified IRF5 high and low subgroups in SLE, and support the potential of IRF5 as a biomarker in precision medicine. We established a solid-phase proximity ligation assay (SP-PLA) for IRF5 detection using a commercially available polyclonal antibody, which was benchmarked against two in-house recombinant antibodies. A linear calibration curve was generated using recombinant IRF5 protein (range 0.01-100 pg/µL), with a limit of detection between 0.01 and 0.05 pg/µL. EDTA-plasma samples from three SLE subgroups (n = 25 per group) were analysed. IRF5 was detectable in all SLE plasma samples using SP-PLA (mean 0.63 pg/µL; sd 1.92 pg/µL; maximum 13.54 pg/µL). The IRF5 high SLE subgroup showed significantly higher IRF5 plasma levels than the IRF5 low SLE subgroup (Dunn's post-hoc test, adjusted p < 0.05). The SP-PLA enabled sensitive and specific detection of low-level IRF5 in plasma and confirmed the presence of IRF5 high and low subgroups in SLE using a quantitative method. These findings support the potential of IRF5 as a biomarker, but validation in independent cohorts is required. The assay may facilitate patient stratification in future research and precision medicine approaches targeting the interferon pathway.

7 June 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
ANA. Notarnicola
A. Notarnicola
CHC. Hellstrom
C. Hellstrom
BHB. Horuluoglu
B. Horuluoglu
CPC. Preger
C. Preger
FBFrancesco Bonomi
Francesco Bonomi
ILI. E. Lundberg
I. E. Lundberg
Background Autoantibodies are found in up to 80% of patients with idiopathic inflammatory myopathies (IIM) and are associated with distinct clinical phenotypes [1]. Autoantibodies targeting cytosolic 5´-nucleotidase 1A (anti-cN1A) are currently the only known serum biomarker for the subgroup inclusion body myositis (IBM) (2), although detected even in other autoimmune diseases. Objectives To identify new autoimmune targets in IIM by antigen bead array assay. Methods In a first cross-sectional exploratory study, 357 antigens representing 268 proteins were incubated with plasma samples from 219 IIM (108 Polymyositis (PM), 80 Dermatomyositis (DM) and 31 IBM) patients, 349 Systemic Lupus Erythematosus (SLE) patients and 306 population controls for screening of IgG reactivity by antigen bead array. All samples were identified in the local biobank of the Rheumatology clinic, Karolinska University Hospital. Interesting results obtained for the IBM subgroup were then validated in an independent larger cohort of 287 patients with IBM followed at nine European rheumatological or neurological centers. IBM serum samples were explored by antigen bead array and results validated by western blot. As controls, serum samples from 30 patients with PM and 30 with DM, HLA-matched with the IBM Swedish cohort, were included. Demographics, laboratory, clinical, and muscle biopsy data of the IBM cohort was retrieved. Results In the exploratory study IgG reactivity towards NADH dehydrogenase 1 α subcomplex 11 (NDUFA11), a subunit of the membrane-bound mitochondrial respiratory chain complex I, was discovered with higher frequency in the IBM (9,7%) than PM (2,8%) and DM samples (2,5%), although the difference was not statistically significant. Anti-NDUFA11 IgG was also found in 2,3% of SLE and 2,6% of population control samples. In the validation study anti-NDUFA11 autoantibodies were detected in 11/287 IBM patients (3,8%), 0/30 PM and 0/30 DM patients. Reactivity against NDUFA11 could be confirmed by western blot (Table 1, Figure 1). The eleven anti-NDUFA11 positive patients showed a trend of lower frequency of wheelchair/walker ever use and higher creatine kinase levels at time of IBM diagnosis compared to the anti-NDUFA11 negative group. Ragged red fibers were significantly more prevalent in anti-NDUFA11 positive than negative patients (p=0.04). Anti-cN1A autoantibodies were detected in 98/287 (34,1%) of IBM, 3/30 (10%) DM and 9/29 (31%) PM patients, p=0.03. Coexistence of anti NDUFA11 and anti-cN1A antibodies was observed in 3 IBM patients. Conclusion Our results reveal a new autoimmune target in the mitochondrial respiratory chain complex I that might be specifically associated with IBM. This is of particular interest as mitochondrial abnormalities are known histological findings in muscle biopsies of IBM patients. References [1]Galindo-Feria AS, Wang G, Lundberg IE. Autoantibodies: Pathogenic or epiphenomenon. Best Pract Res Clin Rheumatol. 2022;36(2):101767. [2]Herbert MK,et al. Disease specificity of autoantibodies to cytosolic 5’-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2016;75(4):696-701. NDUFA11 protein fragments (PrESTs) Legend Amino acid sequence and molecular weight of the protein fragments loaded on the western blot gel. NDUFA11, NADH dehydrogenase 1 α subcomplex 11; His6ABP, six histidine and albumin binding protein. Validation of bead array assay results with western blot Legend Western blot showing the reactivity of two IBM patients against the NDUFA11 protein fragments (PrEST1,2,3) expressed with a His6ABP tag. Patient#1 was reactive to PrEST1 and not to PrEST2 and 3 in the bead array assay while patient#2 did not display any reactivity. NDUFA11, NADH dehydrogenase 1 α subcomplex 11; His6ABP, six histidine and albumin binding protein. Disclosure of Interests Antonella Notarnicola: None declared, Cecilia Hellstrom: None declared, Begum Horuluoglu: None declared, Charlotta Preger: None declared, Francesco Bonomi: None declared, Boel De Paepe: None declared, Jan De Bleecker: None declared, Anneke J. van der Kooi: None declared, Marianne de Visser: None declared, Sabrina Sacconi: None declared, Pedro Machado: None declared, Umesh A. Badrising: None declared, Anke Rietveld: None declared, Ger Pruijn: None declared, Simon Rothwell: None declared, James B. Lilleker: None declared, Hector Chinoy: None declared, Olivier Benveniste: None declared, Elisabet Svenungsson: None declared, Helena Idborg: None declared, Per-Johan Jakobsson: None declared, Peter Nilsson: None declared, Ingrid E. Lundberg Shareholder of: stock shares in Roche and Novartis, Consultant of: Consulting fees from Corbus Pharmaceuticals, Inc and research grants from Astra Zeneca and has been serving on the advisory board for Astra Zeneca, Bristol Myers Squibb, EMD Serono Research & Development Institute, Argenx, Octapharma, Kezaar, Orphazyme, Pfizer and Janssen.

5 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
FEFabricio Espinosa-Ortega
Fabricio Espinosa-Ortega
SCSilvia Cavalli
Silvia Cavalli
RARyan A. Adams
Ryan A. Adams
LGLauren Guy
Lauren Guy
CPCharlotta Preger
Charlotta Preger
ANAntonella Notarnicola
Antonella Notarnicola
Anti-Jo1 autoantibodies (aJo1), targeting histidyl-tRNA synthetase (HisRS), are the most common diagnostic biomarker of anti-synthetase syndrome (ASyS), although their value for disease monitoring remains unclear. We investigated longitudinal aJo1 levels and their associations with disease activity, clinical phenotype, and prognosis in 50 patients with aJo1-positive ASyS. Serum samples (n = 159), collected near diagnosis (baseline) and during follow-up at Karolinska University Hospital were analyzed using an in-house electrochemiluminescence immunoassay to measure aJo1 and HisRS levels. Prospectively collected clinical and disease activity data were evaluated at each sampling time and last follow-up; remission/low disease activity was defined as physician global assessment (PhGA) ≤20 and/or physician judgment. Longitudinal aJo1 levels showed individual variability and generally paralleled physician/patient global assessments and extra-muscular disease activity. HisRS levels were inversely correlated with aJo1 levels (rho = -0.50, p < 0.001). Higher baseline aJo1 levels were associated with development of interstitial lung disease (ILD) (p < 0.05), and a discriminative baseline cut-off for ILD was identified. aJo1 levels declined significantly between the first and second samples (median reduction 71%; p < 0.001). Patients achieving remission/low disease activity at the second sampling exhibited a greater reduction in aJo1 levels than those with moderate/high disease activity (82% vs 0%, p = 0.007). Higher baseline aJo1 levels were also associated with better outcomes at the last evaluation. These findings suggest that longitudinal aJo1 levels reflect changes in disease activity and that baseline aJo1 levels may have prognostic value, supporting their potential use as biomarkers for disease monitoring in ASyS.

27 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
YLYuebei Luo
Yuebei Luo
JKJosefin Kenrick
Josefin Kenrick
AGAngeles S Galindo-Feria
Angeles S Galindo-Feria
ANAntonella Notarnicola
Antonella Notarnicola
ANAna Daniela Ulloa Navas
Ana Daniela Ulloa Navas
BHBegum Horuluoglu
Begum Horuluoglu
Objective: Tissue-specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue-derived proteins. Thus we applied a dual antibody-based proximity extension assay to profile the plasma proteome in subtypes of patients with IIM. Methods: Plasma samples from 201 patients diagnosed with IIM at Karolinska University Hospital were analyzed using Olink. Clinical manifestations, disease activity measurements, and laboratory results were collected. First, we evaluated differential protein abundance across IIM subtypes. Then we calculated tissue scores for each disease subtype using tissue gene expression databases. Finally, interferon (IFN) and complement pathway scores were calculated. Results: Plasma from patients with dermatomyositis was enriched for IFN signaling and skin associated proteins, anti-synthetase syndrome (ASyS) for lung associated proteins, immune-mediated necrotizing myopathy (IMNM) for muscle associated proteins, and inclusion body myositis for T cell response proteins. Patients with IMNM showed the highest tissue score for skeletal muscles, and ASyS for lung tissue score. Skeletal muscle scores correlated strongly with muscle disease activity visual analog scale scores, creatinine kinase levels, and muscle weakness score. Patients with interstitial lung disease along with and those with anti-Jo1 autoantibodies showed differential enrichment of surfactant proteins and IFN pathway activation. Conclusions: Circulatory proteome is a promising tool to capture distinct tissue-specific responses that correlate with disease activity and tissue injury in patients with IIM.